Why Nice was right to say no – for now – to new Alzheimer’s drugs

By Paul Atkinson, Senior Research Fellow, History of Health and Medicine, University of Liverpool
Sally Sheard, Chair Professor, History of Medicine, University of Liverpool

The UK’s National Institute for Health and Care Excellence (Nice) has declined to recommend two new Alzheimer’s drugs for routine NHS use in England. While disappointing for some families affected by dementia, this decision reflects a cautious and evidence-based approach that protects patients and public funds.

The drugs in question – lecanemab, made by Eisai, and donanemab…

Read complete article

~	South Korea: Human Rights Issues for New Government

~	A chance discovery of a 350 million-year-old fossil reveals a new type of ray-finned fish

~	Ceasefires like the one between Iran and Israel often fail – but an agreement with specific conditions is more likely to hold

~	Rwanda: Opposition Leader Arrested

~	World News in Brief: Türk speaks out on sexual violence, Brazil floods update, Nicaraguan human rights violations

~	Playful or harmful? David Seymour’s posts raise questions about what’s OK to say online

~	A chance discovery of a 365-million-year-old fossil reveals a new type of ray-finned fish

~	Ibn Battuta, a 14th-century judge and ambassador, travelled further than Marco Polo. The Rihla records his adventures

~	Video games can help trans players feel seen and safe. It all starts with design

~	The ancients also had to deal with a cost-of-living crisis. Here’s how they managed